Background-Collagen
G
rowing evidence from experimental studies 1,2 and clinical trials [3] [4] [5] [6] suggest that cell therapy can restore perfusion and improve function in ischemic and/or infarcted myocardium. Circulating progenitor cells (CPCs) have been shown to contribute to neovascularization in ischemic tissues, where they may differentiate into endothelial cells in situ and result in "vasculogenesis." [7] [8] [9] CPCs can be obtained by noninvasive means, thus providing the potential for autologous clinical use.
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However, stem/progenitor cell therapy is hindered by a low rate of engraftment and low persistence of cells in the target tissue. Depending on the method of delivery and the cell fraction used, transplanted cells can quickly fade from the target tissue in a matter of hours to a few days. 10, 11 Therefore, insufficient cell numbers and inadequate cellular interactions may not allow for an optimal therapeutic effect. Furthermore, delivery of cells to other nonspecific body sites constitutes an unwanted potential side effect. Considering the rapid loss of the delivered cells and the modest benefits of cardiac cell therapy using bone-marrow derived cells observed in clinical studies, 5, 6 it is likely that improvements in stem/progenitor cell delivery, engraftment and survival will be needed for more effective restoration of myocardial function.
Previous work, including our own, has shown that tissue engineered collagen-based matrices can support multiple tissues and cell types, 12, 13 and constitute suitable cell delivery vehicles. [13] [14] [15] It has been hypothesized that the collagen, which mimics the extracellular matrix, may provide local physical retention and a good platform for cell seeding during direct cell transplantation. 14 However, the evaluation of the ability of matrices to improve cell viability and engraftment has so far been limited primarily to histological assessment of tissue at a single time point. This study was therefore designed to use in vivo imaging to examine one mechanism by which a collagen matrix may enhance the short-term effects of CPC transplantation through improved early retention of transplanted cells.
To this end, we used small animal positron-emission tomography (PET), which is an advanced nuclear imaging technology with high sensitivity and high spatial resolution.
PET not only provides the potential for determining the nature of transplanted cells and of their progeny in vivo, but also offers serial monitoring capabilities that add to the clinical relevance of this modality. PET imaging with 2-[
18 F]fluoro-2-deoxy-D-glucose ( 18 F-FDG) cell labeling has been used to track a few types of cells, such as monocytes, bone marrow-derived cells, hematopoietic stem cells, in animal 16 and human studies. 17, 18 However, use of 18 F-FDG to label CPCs for the assessment of delivery matrix effects on transplanted cells has not been reported.
In the present study, we evaluated the feasibility of using 18 F-FDG to label CPCs for tracking by small animal PET and examined the effect of collagen-based matrices on the early retention of transplanted CPCs and their distribution to nonspecific tissues in a rat model of hind limb ischemia.
Methods

Cell Isolation and Culture
Human CPC procurement procedures were approved by the Human Research Ethics Board of the University of Ottawa Heart Institute. Total peripheral blood mononuclear cells were freshly isolated (with informed consent) from the blood of volunteer, healthy human donors by Histopaque 1077 (Sigma-Aldrich, Oakville, Canada) densitygradient centrifugation of buffy coats, as described previously. 19 Briefly, cells were cultured on fibronectin-coated plates in endothelial basal medium-2 (Clonetics, Guelph, Canada) supplemented with EGM-2-MV-SingleQuots (Clonetics). 19 After 4 days, the adherent population (CPCs) was collected.
Collagen Matrix Preparation
Similar to methods described previously, 14 collagen-based matrices (pH 7.5) were prepared on ice. Briefly, matrices consisted of a mixture of blended neutralized type I rat tail tendon collagen (0.4%, wt/vol; Becton Dickinson, Mississauga, Canada) and chondroitin 6-sulfate (1:6, wt/wt; Sigma), cross-linked with 0.02% (vol/vol) glutaraldehyde and followed by glycine termination of unreacted aldehyde groups. This formulation allowed the matrix to thermogel at 37°C, following injection into animal tissue.
18
F-FDG Cell Labeling
CPCs were incubated with 18 6 cells, in 1, 3, or 5 mL of media) were tested to optimize the efficiency of the labeling procedure. In select experiments, insulin (0.1 U/mL) and heparin (10 U/mL) were added to the incubation in an attempt to improve labeling efficiency. At the end of incubation, cells were washed in PBS to remove unbound radioactivity. The radioactivity was measured both in cells and in the supernatant by using a dose calibrator (Capintec, Ramsey, NJ). With correction for radiolabel decay, cell-labeling efficiency was calculated as the activity in cells over the total activity used in the incubation.
Stability and Viability of Labeled Cells
To assess the stability of the labeling procedure, labeled cells were rinsed and centrifuged, and the cell pellet was resuspended in 2 mL PBS and incubated at 37°C for 2 hours. The retention of 18 F-FDG within CPCs was calculated as above. To determine the effects of labeling on cell viability, labeled or nonlabeled cells (1ϫ10 6 ) suspended in 1.0 mL endothelial basal medium were plated and incubated for an additional 0.5 hours, 24 hours, or 5 days. Cell viability was assessed using the Vi-CELL analyzer (Beckman Coulter, Mississauga, Canada) with a Trypan Blue Dye Exclusion Method. 18 
Retention of
F-FDG in Matrices
18 F-FDG-labeled CPCs (1ϫ10 6 ) in 50 L of PBS or 18 F-FDG alone (using the same radioactivity and volume as the labeled CPCs) were added to the matrix solution (450 L) on ice. Gels were plated at 500 L per well in 24-well flat-bottom plates (VWR, Mississauga, Canada) and incubated at 37°C for 60 minutes to allow complete gelation of the matrix. Matrix gels were transferred into 2 mL PBS and incubated at 37°C for 2 hours. After incubation, the radioactivity in matrices was counted to determine the retention of 18 F-FDG in matrices. Controls consisted of 1ϫ10 6 18 F-FDG-labeled cells in 500 L of PBS.
Hind Limb Ischemia Animal Model
Procedures were performed with the approval of the University of Ottawa Animal Care Committee, in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. The left proximal femoral artery of anesthetized (2% isoflurane) 8-to 9-week-old Sprague Dawley rats (Charles River, Wilmington, Mass) was ligated to induce ischemia, as previously described. 20 Survival for all treatment groups was 100%. Two weeks after ligation, anesthetized rats randomly received one of the following treatments, administered by intramuscular injection into the ischemic thigh muscle, using a 28-gauge needle: (1) 2ϫ10 6 18 F-FDG-labeled CPCs (34.7 to 56.9 Ci) in 400 L of matrix (nϭ15); (2) 2ϫ10 6 18 F-FDG-labeled CPCs (32.0 to 61.0 Ci) in 400 L PBS (nϭ15); (3) Small Animal PET Imaging for Localization of 18 
F-FDG-Labeled CPCs
For some animals (nϭ3 to 4 per treatment group), whole body 18 F-FDG images (150 minutes postinjection) were acquired for 15 minutes using the Inveon small animal PET scanner (Siemens, Knoxville, Tenn). Images were reconstructed using OSEM2D, resulting in a reconstructed image resolution of Ϸ1.3 mm. To determine relative retention in the injected hind limb, Inveon Research Workplace (Siemens, Knoxville, Tenn) was used to draw 1 cuboid volume that completely encompassed the hind limb, and a second cuboid volume that contained the whole body. After correcting for injected activity, total counts in both volumes were expressed as a retention ratio of hind limb/whole-body counts.
Biodistribution of 18 F-FDG Labeled CPCs
Although under anesthetic, rats were euthanized by cervical dislocation (at 180 minutes postinjection) and their tissues were dissected. Biodistribution of the specific radioactivity accumulation in different tissues was determined by a ␥ counter (PerkinElmer Life and Analytic Sciences, Waltham, Mass), and the tissues were weighed. Data are expressed as percentage of the injected dose per gram of wet tissue for all tissues other than the ischemic hind limb, and as percentage of the injected dose per organ for the ischemic hind limb, to account for differences in harvested and injected hind limb tissue locations. 21 
Immunofluorescence Assessment
Hind limb muscles were dissected from 0.5 cm above to 0.5 cm below the marked injection site, fixed with 4% paraformaldehyde, and sectioned at 2.5 mm thickness to ensure equivalent sampling. Tissue samples were stored in 10% neutral buffered formalin, paraffin embedded, and slides were prepared using 5-m serial sections. According to the manufacturer's protocol, transplanted human CPCs were localized by immunofluorescence staining using antihuman mitochondria antibodies (1:40; Chemicon, Temecula, Calif). The sections were mounted with mounting medium containing 4Ј,6-diamidino-2Ј-phenylindole (Vector Laboratories, Burlingame, Calif) to label cell nuclei. 
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Results
F-FDG Cell-Labeling Efficiency Depends Primarily on the Concentration of CPCs
Using 1ϫ10 6 CPCs, there was no correlation between the retention and the amount of 18 F-FDG in the incubation (Table) . Therefore, within the 18 F-FDG dose range used, CPC labeling efficiency was not 18 F-FDG-dose dependent (Pϭ0.18, nϭ5/group).
A total of 2ϫ10 6 CPCs and 2 mCi 18 F-FDG were incubated in 3 different volumes ( Figure 1A ). The highest 18 F-FDG retention in CPCs (7.6Ϯ4.4%, nϭ12) was obtained in the most concentrated group (ie, 1 mL total incubation volume). 18 F-FDG accumulation decreased as incubation volumes were increased, indicating that the labeling efficiency of 18 F-FDG was dependent on the concentration of CPCs (rϭ0.61, PϽ0.001, nϭ9), with an overall labeling efficiency range of 1.5% to 12% ( Figure 1B) . Additional experiments revealed that insulin and heparin did not increase the retention of 18 F-FDG in CPCs (data not shown). 
Labeled CPCs Exhibit Good Short-Term Stability and Viability
The retention of 18 F-FDG in CPCs was 42.1Ϯ3.1% (nϭ6) after a 2-hour incubation, indicating that labeled cells showed efflux of radioactivity into media.
To investigate the effect of 18 F-FDG labeling on cells, labeled cell viability was measured at 0.5 hours, 24 hours, or 5 days after labeling. As shown in Figure 2 , radiolabeling had no effect on CPC viability (Pϭ0.21) up to 24 hours postlabeling. However, there was a slight reduction in viability (Ϫ15.9Ϯ6.6%) after 5 days (PϽ0.05). 
Collagen Matrices Maintain Labeled Cells Within the Target Tissue and Minimize Delivery to Nonspecific Tissues and Organs
Determination by PET Imaging of 18 F-FDG-Labeled Cells
Small animal PET whole-body imaging was performed in rats after treatment with 18 F-FDG-labeled cells with or without the matrix, to assess the ability of matrices to improve retention of the transplanted CPCs in the hind limb. At 150-minute postinjection (Figure 4) , greater signal intensities in the ischemic hind limb relative to the whole body were observed when CPCs were delivered with the matrix. The retention ratio of 18 F-FDG radioactivity in the ischemic hind limb to whole-body 18 F-FDG radioactivity for hind limbs receiving CPCs in the matrix (0.44Ϯ0.08) was significantly greater than that observed for labeled CPCs in PBS (0.22Ϯ0.13; Pϭ0.040), and to 18 F-FDG injected in the matrix or in PBS (0.10Ϯ0.05 and 0.11Ϯ0.05, respectively; PϽ0.005). PET imaging results also indicate that the accumulation of 18 F-FDG in heart, bladder, and other nonspecific organs was lower when CPCs were delivered with matrix versus the other treatment groups (Figure 4 ).
Determination by Biodistribution of 18 F-FDG-Labeled Cells
For confirmation, biodistribution of the specific radioactivity accumulation in different organs was determined after completion of PET scans. As shown in Figure 5 , with use of the matrix there was a significant increase in retention (69.6%, Pϭ0.021) of 18 F-FDG-labeled CPCs within the ischemic hind limb muscle, and an overall reduction (by 14.8% to 31.4%, PϽ0.05) of labeled cell distribution to nontarget tissues, including the heart, lung, kidney, spleen, liver, and brain.
Determination by Immunofluorescence Analysis of Transplanted Cells
The retention of transplanted human CPCs in the ischemic hind limb was also confirmed by immunofluorescence analysis, using antihuman mitochondria antibody and 4Ј,6-diamidino-2Ј-phenylindole ( Figure 6 ). The percentage of 
Discussion
The main findings of this study are (1) that use of a collagen-based matrix increased the early retention of CPCs delivered in vivo (observed only 2 to 3 hours posttransplantation); (2) that a collagen-based matrix minimized the distribution of CPCs to nonspecific tissues; (3) that 18 F-FDG is a usable tracer for monitoring transplanted CPCs, and 18 F-FDG-labeled CPCs in the group delivered in matrix (nϭ15) was significantly greater in the target tissue (ischemic hind limb). B, Radioactivity in the nonspecific tissues. There was an overall reduction of labeled-cell distribution in kidney, spleen, and other nonspecific tissues.
# PϽ0.05 versus FDG (nϭ12); P Ͻ0.05 versus FDG with the matrix (nϭ12); *PϽ0.05 versus FDG-labeled CPCs (nϭ15).
provides a promising platform for the development of noninvasive PET imaging approaches for trafficking of CPC delivery within matrices in real time; and (4) that the success of the PET imaging methods in evaluating the effect of the matrix on CPC transplantation was validated by 2 conventional methodologies (biodistribution and immunofluorescence). Our study therefore introduces a novel concept that in addition to improving the long-term engraftment of transplanted cells, a collagen delivery matrix may also enhance the short-term effects of cell therapy because differences in cell retention were observed at an early stage posttransplantation.
Stem cells and/or progenitor cells are being widely investigated as a potential therapy for ischemic heart disease. Satisfactory cell deposition and engraftment in the target area are considered likely therapeutic prerequisites. The use of CPCs for cardiac angiogenic activity has previously resulted in some benefits, but the retention and survival of implanted cells in the myocardium is only between 1% and 10%. 22 The development of tissue engineered matrices for the delivery and support of transplanted cells has recently attracted interest in the cardiac field. Collagen-based biomaterials have been developed to support cell growth and for the restoration of myocardial infarction. [23] [24] [25] [26] The advantages of collagen matrices are their large surface area for cell seeding, porosity for capillary in-growth, stability for mechanical support, biodegradability, and minimal immunogenicity. 23, 24 Previous work from our group indicated that in vitro adhesion of the CPC derived CD133 ϩ cells was greatest on a collagen type I substrate; and use of a collagen-based matrix for the delivery of CPCs into ischemic hind limbs of rats improved the retention of the transplanted cells and increased tissue vascularization, as determined by immunohistochemical analysis performed 2 weeks after transplantation. 14 In this study, noninvasive in vivo PET imaging and subsequent biodistribution and immunofluorescence analysis demonstrated related observations at earlier time points after transplantation than previously investigated. CPC retention in the ischemic hind limb muscle was Ϸ11% of injected dose at 180 minutes after injection without the matrix. With use of the matrix, retention was enhanced by Ϸ70% in the target tissue.
To date, cardiac cell therapy has resulted only in modest clinical benefits, 5, 6 perhaps limited by the low retention and survival of implanted cells. It has been demonstrated that the loss of injected cells from the target tissue occurs at an early stage posttransplantation, 10,11,22 but their effects can be sustained by host tissues that are induced by the transplanted cells to express humoral factors involved in angiogenesis, antiapoptosis, and chemoattraction of bone marrow cells. 10 Therefore, the observation that our collagen matrix improved the very early retention of cells within the target tissue suggests that its use may confer enhanced short-term therapeutic cell effects in addition to its benefits to long-term cell engraftment. It is conceivable that by minimizing the rapid loss of transplanted cells, the collagen matrix may augment and/or prolong the cell transplant-mediated host humoral response.
The ability to assess the engraftment and survival of transplanted cells is also of importance for the study of cell-based therapeutic strategies. Traditionally, the fate of transplanted cells is assessed by postmortem histological examination at a single time point in animal studies. For visualization, ex vivo cell labeling methods are used before transplantation using a vital dye (eg, 4Ј,6-diamidino-2Ј-phenylindole), a thymidine analog (eg, 5-bromodeoxyuridine) or a conventional reporter gene (eg, green fluorescent protein). Alternatively, established radioisotope methods used in clinical nuclear medicine offer an attractive option for cell imaging, with the advantage of noninvasive cell tracking at several time points. The present study demonstrated that PET imaging with 18 F-FDG cell labeling was feasible for the assessment of CPC retention and distribution in the early stages of transplantation with and without a matrix. To our knowledge, this is the first study using PET imaging to investigate and demonstrate the effect of collagen matrices on cell transplantation in vivo. 18 F-FDG is an attractive radiotracer for labeling stem cells because it enables PET imaging of cell tracking in vivo, and exploits normal metabolic activity of target cells, thereby reducing any risk of functional alteration. In this study, we successfully labeled human CPCs with 18 F-FDG with minimal alteration of viability. The viability of labeled cells was preserved up to 24 hours, with a slight subsequent reduction observed at 5 days. Our results also demonstrated that cell-labeling efficiency of 18 F-FDG was CPC-concentration dependent but not FDG-dose dependent. Similar observations have been reported in studies using 111 In or 99m Tc. 27, 28 Because only viable cells will retain 18 F-FDG in the cytoplasm, an added benefit to its use is that retention of 18 F-FDG might reflect the viability state of the cells. 17 However, a possible limitation of labeling cells with 18 F-FDG is that significant leakage of the radiotracer after initial cellular accumulation may occur. Several studies using 18 F- FDG have reported a labeling efficiency of Ͻ10% for some types of stem cells because of a high efflux rate in the first hour postlabeling. Ma et al 29 showed that rat mesenchymal stem cells can be labeled with 18 F-FDG but 98% release of the radiotracer occurs in the washing process. Our results also showed a significant rate of radiolabel release from CPCs during the washing process. Stability studies on labeled cells showed a Ϸ50% label loss after 2-hour incubation. Although insulin has been shown to improve 18 F-FDG retention in cells, it was not effective in improving the labeling efficiency in CPCs. 17 It is possible that CPCs may have an insufficient level of G-6-phosphatase activity, or perhaps insulin does not have an inhibitory effect on G-6-phosphatase activity in CPCs. 30 Importantly, despite the dosage loss, the radioactivity could still be monitored by PET in vivo.
Another limitation of 18 F-FDG cell labeling is the rather short half-life of 18 F (110 minutes) that only permits the monitoring of cell fate for several hours. Advances in nanotechnology are enabling the development of new PET agents with improved sensitivity for the tracking of cells using long-lived radionuclides. For example, 64 Cu-labeled nanoparticles have been used to image the macrophages in inflammatory atherosclerosis, 31 and although not yet widely available, agents such as these may provide an appealing alternative for long-term or repeated imaging.
In summary, 18 F-FDG is a usable tracer for monitoring transplanted CPCs, and provides a promising platform for the development of noninvasive PET imaging approaches for trafficking of CPC delivery within matrices in real time. This study used PET imaging and traditional confirmatory techniques to demonstrate that collagen-based matrices significantly improved the very early retention of transplanted CPCs in the ischemic tissue and limited their nonspecific distribution. This mechanism conferred by the matrix may have implications on the effects of cell therapy at the early stages after transplantation in addition to the long-term benefits of improved cell engraftment.
